Skip Nav Destination
Issues
15 June 2015
-
Cover Image
Cover Image
![issue cover]()
The cover shows head and neck squamous cell carcinoma (UMSCC1) xenograft tissue sections harvested after treatment with the dual PI3k/mTOR inhibitor PF-05212384. Immunohistochemical staining demonstrates a significant reduction in phospho-S6 fluorescence (green) with intravenous PF-05212384 treatment. For details, see the article by Leiker and colleagues on page 2792 of this issue.Close Modal - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
20th Anniversary Commentary
CCR Translations
CCR Perspectives in Drug Approval
FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma
Hyon-Zu Lee; Virginia E. Kwitkowski; Pedro L. Del Valle; M. Stacey Ricci; Haleh Saber; Bahru A. Habtemariam; Julie Bullock; Erik Bloomquist; Yuan Li Shen; Xiao-Hong Chen; Janice Brown; Nitin Mehrotra; Sarah Dorff; Rosane Charlab; Robert C. Kane; Edvardas Kaminskas; Robert Justice; Ann T. Farrell; Richard Pazdur
Molecular Pathways
Reviews
Cancer Therapy: Clinical
A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors
Elena Gabriela Chiorean; Patricia LoRusso; Robert Matthew Strother; Jennifer R. Diamond; Anne Younger; Wells A. Messersmith; Lieve Adriaens; Liming Liu; Richard J. Kao; Albert Thomas DiCioccio; Ana Kostic; Russell Leek; Adrian Harris; Antonio Jimeno
A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
Naval Daver; Yanis Boumber; Hagop Kantarjian; Farhad Ravandi; Jorge Cortes; Michael E. Rytting; Jitesh D. Kawedia; Jordan Basnett; Kirk S. Culotta; Zhihong Zeng; Hongbo Lu; Mary Ann Richie; Rebecca Garris; Lianchun Xiao; Wenbin Liu; Keith A. Baggerly; Elias Jabbour; Susan O'Brien; Jan Burger; Linda J. Bendall; Deborah Thomas; Marina Konopleva
Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma
Steven G. DuBois; Susan Groshen; Julie R. Park; Daphne A. Haas-Kogan; Xiaodong Yang; Ethan Geier; Eugene Chen; Kathy Giacomini; Brian Weiss; Susan L. Cohn; M. Meaghan Granger; Gregory A. Yanik; Randall Hawkins; Jesse Courtier; Hollie Jackson; Fariba Goodarzian; Hiroyuki Shimada; Scarlett Czarnecki; Denice Tsao-Wei; Judith G. Villablanca; Araz Marachelian; Katherine K. Matthay
TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer
Andres Forero-Torres; Katherine E. Varley; Vandana G. Abramson; Yufeng Li; Christos Vaklavas; Nancy U. Lin; Minetta C. Liu; Hope S. Rugo; Rita Nanda; Anna M. Storniolo; Tiffany A. Traina; Sujata Patil; Catherine H. Van Poznak; Julie R. Nangia; William J. Irvin, Jr; Helen Krontiras; Jennifer F. De Los Santos; Paul Haluska; William Grizzle; Richard M. Myers; Antonio C. Wolff; on behalf of the Translational Breast Cancer Research Consortium (TBCRC)
Author Choice
A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma
Markus Hansson; Peter Gimsing; Ashraf Badros; Titti Martinsson Niskanen; Hareth Nahi; Fritz Offner; Morten Salomo; Elisabeth Sonesson; Morten Mau-Sorensen; Yvonne Stenberg; Annika Sundberg; Ingrid Teige; Jan Van Droogenbroeck; Stina Wichert; Maurizio Zangari; Björn Frendeus; Magnus Korsgren; Martine Poelman; Guido Tricot
Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib
Justin F. Gainor; Daniel S.W. Tan; Tomasso De Pas; Benjamin J. Solomon; Aziah Ahmad; Chiara Lazzari; Filippo de Marinis; Gianluca Spitaleri; Katherine Schultz; Luc Friboulet; Beow Y. Yeap; Jeffrey A. Engelman; Alice T. Shaw
Personalized Medicine and Imaging
Author Choice
CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients
Fabian Birzele; Edgar Voss; Adam Nopora; Konrad Honold; Florian Heil; Sabine Lohmann; Henk Verheul; Christophe Le Tourneau; Jean-Pierre Delord; Carla van Herpen; Devalingam Mahalingam; Andrew L. Coveler; Valerie Meresse; Stefan Weigand; Valeria Runza; Michael Cannarile
Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019
Costanza Paoletti; Yufeng Li; Maria C. Muñiz; Kelley M. Kidwell; Kimberly Aung; Dafydd G. Thomas; Martha E. Brown; Vandana G. Abramson; William J. Irvin, Jr; Nancy U. Lin; Minetta C. Liu; Rita Nanda; Julie R. Nangia; Anna M. Storniolo; Tiffany A. Traina; Christos Vaklavas; Catherine H. Van Poznak; Antonio C. Wolff; Andres Forero-Torres; Daniel F. Hayes; on behalf of the Translational Breast Cancer Research Consortium (TBCRC)
Cancer Therapy: Preclinical
Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib
Inger S. Nijhof; Richard W.J. Groen; Willy A. Noort; Berris van Kessel; Regina de Jong-Korlaar; Joost Bakker; Jeroen J.L. van Bueren; Paul W.H.I. Parren; Henk M. Lokhorst; Niels W.C.J. van de Donk; Anton C.M. Martens; Tuna Mutis
Author Choice
The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient–Derived Xenograft Models
Alwin G. Schuller; Evan R. Barry; Rhys D.O. Jones; Ryan E. Henry; Melanie M. Frigault; Garry Beran; David Linsenmayer; Maureen Hattersley; Aaron Smith; Joanne Wilson; Stefano Cairo; Olivier Déas; Delphine Nicolle; Ammar Adam; Michael Zinda; Corinne Reimer; Stephen E. Fawell; Edwin A. Clark; Celina M. D'Cruz
Biology of Human Tumors
Prognostic Significance of Tryptophan Catabolism in Adult T-cell Leukemia/Lymphoma
Ayako Masaki; Takashi Ishida; Yasuhiro Maeda; Susumu Suzuki; Asahi Ito; Hisashi Takino; Hiroka Ogura; Haruhito Totani; Takashi Yoshida; Shiori Kinoshita; Tomoko Narita; Masaki Ri; Shigeru Kusumoto; Atsushi Inagaki; Hirokazu Komatsu; Akio Niimi; Ryuzo Ueda; Atae Utsunomiya; Hiroshi Inagaki; Shinsuke Iida
The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28–Costimulated T Cells Prepared for Adoptive Therapy
Emese Zsiros; Priyanka Duttagupta; Denarda Dangaj; Hongzhe Li; Renee Frank; Thomas Garrabrant; Ian S. Hagemann; Bruce L. Levine; Carl H. June; Lin Zhang; Ena Wang; Francesco M. Marincola; Davide Bedognetti; Daniel J. Powell, Jr; Janos Tanyi; Michael D. Feldman; Lana E. Kandalaft; George Coukos
Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma
Antonio Calles; Lynette M. Sholl; Scott J. Rodig; Ashley K. Pelton; Jason L. Hornick; Mohit Butaney; Christine Lydon; Suzanne E. Dahlberg; Geoffrey R. Oxnard; David M. Jackman; Pasi A. Jänne
SIRT1/PGC1α-Dependent Increase in Oxidative Phosphorylation Supports Chemotherapy Resistance of Colon Cancer
Thomas T. Vellinga; Tijana Borovski; Vincent C.J. de Boer; Szabolcs Fatrai; Susanne van Schelven; Kari Trumpi; Andre Verheem; Nikol Snoeren; Benjamin L. Emmink; Jan Koster; Inne H.M. Borel Rinkes; Onno Kranenburg
Advertisement
